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Abstract
Background: Inhalational anesthetics have been shown to influence T cell functions both in vitro and in vivo, in
many cases inducing T cell death, suggesting that exposure to these drugs could modify the course of an
autoimmune disease. We tested the hypothesis that in mice immunized to develop experimental autoimmune
encephalomyelitis (EAE), a well established model of multiple sclerosis (MS), treatment with the commonly used
inhalational anesthetic sevoflurane would attenuate disease symptoms.
Methods: C57Bl6 female mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide residues
35 to 55 to induce a chronic demyelinating disease. At day 10 after immunization, the mice were subjected to 2 h
of 2.5% sevoflurane in 100% oxygen, or 100% oxygen, alone. Following treatment, clinical scores were monitored
up to 4 weeks, after which brain histology was performed to measure the effects on astrocyte activation and
lymphocyte infiltration. Effects of sevoflurane on T cell activation were studied using splenic T cells isolated from
MOG peptide-immunized mice, restimulated ex vivo with MOG peptide or with antibodies to CD3 and CD28,
and in the presence of different concentrations of sevoflurane. T cell responses were assessed 1 day later by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for proliferation, lactate dehydrogenase
(LDH) release for cell death, and inflammatory activation by production of interleukin (IL)-17 and interferon (IFN)γ.
Results: Clinical scores in the oxygen-treated group increased until day 28 at which time they showed moderate to
severe disease (average clinical score of 2.9). In contrast, disease progression in the sevoflurane-treated group
increased to 2.1 at day 25, after which it remained unchanged until the end of the study. Immunohistochemical
analysis revealed reduced numbers of infiltrating leukocytes and CD4+ cells in the CNS of the sevoflurane-treated
mice, as well as reduced glial cell activation. In splenic T cells, low doses of sevoflurane reduced IFNγ production,
cell proliferation, and increased LDH release.
Conclusions: These results are the first to show attenuation of EAE disease by an inhaled anesthetic and are
consistent with previous reports that inhaled anesthetics, including sevoflurane, can suppress T cell activation that,
in the context of autoimmune diseases such as MS, could lead to reduced clinical progression.
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Background
Accumulating data suggests that inhaled anesthetics
(IAs; this includes sevoflurane, isoflurane, and desflur-
ane) can exacerbate inflammation and lead to neuronal
damage in older patients and patients suffering from
Alzheimer’s disease (AD). As an example, sevoflurane
increased caspase activation and apoptosis, altered amyl-
oid precursor protein (APP) processing, and increased
β-amyloid levels in the brains of transgenic mouse mod-
els of AD [1] and in APP-expressing cells [1,2]. These
studies were based on observations that small molecular
weight hydrophobic alkanes can shift oligomerization of
proteins such as β-amyloid towards higher oligomers
and increase cytotoxicity [3-5]. However, it has been
known for many years that certain IAs modulate inflam-
matory responses in peripheral cells and tissues; al-
though usually associated with suppression of cell
activation, in some cases IAs increase inflammatory
responses [6].
Multiple sclerosis (MS) is an autoimmune disease that
affects approximately 400,000 people in the US and over
2 million people worldwide. The exact causes of MS are
not yet precisely known, however, it is well established
that activation of the adaptive immune system leads to
activation and proliferation of T cells that can infiltrate
the central nervous system and release cytokines that
lead to oligodendrocyte damage, demyelination, and
axonal damage. The infiltrating cells also induce inflam-
matory activation of resident glial cells, including astro-
cytes and microglia, which can propagate and maintain
disease pathology. Several treatments which reduce T
cell activation, proliferation, infiltration into the CNS, or
cytokine production are currently used to reduce MS
symptoms; however, additional non-invasive, safe meth-
ods to modulate T cell functions still have potential value
for MS treatment.
In this regard, IAs have been shown to exert signifi-
cant effects on T cells [7-13], influencing their adhesion
properties [14,15] and modifying their inflammatory
responses [12,16-19]. It is thought that regional
anesthesia can improve postoperative recovery by redu-
cing immunosuppression [20]. For example, in normal
adult male mice, 40 minutes with sevoflurane increased
the total number of CD4+ lymphocytes in the spleen
[12]; and in vitro sevoflurane increased P-selectin ex-
pression and platelet:leukocyte adherence in whole blood
[14]; and induced activation of several signaling factors
(apoptosis signal-regulating kinase 1 (ASK1), mitogen-
activated protein kinase kinase (MAPKK)3 and 6; acti-
vating transcription factor 2 (ATF2), and p38 MAPK) in
human Jurkat cells [21]. There are also reports that IAs
reduce T cell activation or activity; for example both
sevoflurane and isoflurane induced apoptosis in whole
peripheral blood mononuclear cells (PBMCs) [11]; and
desflurane reduced cell adhesion molecule expression in
human endothelial cells [22].
These above findings suggest that administration of
IAs could impact the course of an autoimmune disease
such as MS. However, the possible effects of IAs on the
progression of MS symptoms or pathology have not
been characterized. A few case reports suggest that sevo-
flurane does not worsen immediate postoperative recov-
ery [23-25]; however, there are no publications testing
either acute or delayed affects of IAs in animal models
of MS. In view of the above findings we hypothesized
that IA exposure would influence the clinical course of
disease in experimental autoimmune encephalomyelitis
(EAE), a well characterized model of MS. Our findings
indicate that sevoflurane attenuates the progression of
clinical disease in EAE mice, which may be due to sup-
pression of T cell activation.
Methods
Materials
General chemicals and reagents were from Sigma (St
Louis, MO, USA). Secondary antibodies were from Vec-
tor Labs (Burlingame, CA, USA). Myelin oligodendro-
cyte glycoprotein peptide residues 35 to 55 (MOG35-55;
MEVGWYRSPFSRVVHLYRNGK) was purchased from
Anaspec (San Jose, CA, USA).
Mice
Female C57BL/6 mice aged 6 to 8 weeks were purchased
from Charles River Breeding (Cambridge, MA, USA).
Mice were housed five per cage, and kept in a controlled
12 h light/12 h dark environment and provided food ad
libitum. All animal procedures were approved by the
local Institutional Animal Care and Use Committee
(IACUC) committee.
Induction of EAE
EAE was actively induced in using synthetic MOG35-55
as described previously [26]. Mice were injected sub-
cutaneously (two 100 μl injections into adjacent areas in
one hind limb) with an emulsion of 300 μg MOG35-55
dissolved in 100 μl phosphate-buffered saline (PBS),
mixed with 100 μl complete Freund’s adjuvant contain-
ing 500 μg of Mycobacterium tuberculosis (Difco, De-
troit, MI, USA). Immediately after MOG35-55 injection,
the animals received an intraperitoneal injection of per-
tussis toxin (PT; 200 ng in 200 μl PBS). Then, 2 days
later the mice received a second PT injection, and 1 week
later they received a booster injection of MOG35-55. This
protocol leads to an incidence of >90%, low mortality,
average clinical signs between three and four (one or two
hindlimbs with paresis or paralysis), lasting disease with
no recovery for up to 3 months; frank demyelination in
the spinal cords and cerebellum; and neuronal damage
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by 2 months. Clinical signs were scored on a five-point
scale: grade 0, no clinical signs; 1, limp tail; 2, impaired
righting; 3, paresis of one hind limb; 4; paresis of two
hind limbs; 5, death. When a mouse died it was assigned
a score of 5, and that score was carried through for the
rest of the study for statistical analysis. Scoring was per-
formed at the same time each day by an investigator
blinded to allocation.
Treatment with sevoflurane
At 10 days after the booster immunization, at which
point mice begin to show clinical signs, mice were sub-
jected to 2 h 2.5% sevoflurane in 100% oxygen, or as
control to 2 h of 100% oxygen. Anesthetics and oxygen
were provided to mice as a group in a glass chamber.
The gas pressure was continuously monitored. After 2 h,
the mice were allowed to recover and returned to home
cages and monitored for a further 4 weeks. At the end
of the study the mice were killed to prepare brain sec-
tions for histology and immunocytochemical staining.
Tissue preparation and immunohistochemistry
Mouse brains were fixed in 4% paraformaldehyde in 0.1
M phosphate buffer pH 7.6 overnight at 4°C. Dehydra-
tion, embedding, paraffin removal, and sectioning were
performed using standard protocols as described [27].
Serial sagittal sections (8 μm) were obtained by starting
from the midline and included the cerebellum. Following
paraffin removal, antigen retrieval was accomplished
by boiling in 10 mM citrate buffer for 10 minutes,
then blocking with 5% normal donkey serum. Sections
were incubated at 4°C overnight with primary anti-
bodies diluted in 1% normal donkey serum: rat mono-
clonal anti-human glial fibrillary acidic protein (GFAP)
B2.210 at 1:300 [28]. After washing, sections were
incubated 1 h at 37°C with donkey anti-rabbit rhodamine
red-X (RRX) conjugated or donkey anti-rat conjugated
with fluorescein isothiocyanate (FITC) secondary anti-
bodies. Sections were washed, fixed with 3.7% formalde-
hyde in phosphate buffered saline (PBS), quenched in
50 mM ammonium chloride in PBS for 15 minutes,
then final washes performed in PBS with 400 ng/ml
40,6-diamidino-2-phenylindole (DAPI) included in the
second wash. Vectashield mounting fluid (Vector La-
boratories Inc.) was placed onto sections prior to cover
slips placed.
Infiltrating cells
Histological examination for infiltrating cells was per-
formed by staining deparaffinized, washed sections with
hematoxylin and eosin (H&E). Serial sections through
the cerebellum of each mouse were examined for infil-
trates and the number of large (>5,000 μm2) or small
(<5,000 μm2) areas of infiltration counted.
Image analysis
Images were obtained on a Zeiss Axioplan 2 microscope
using an MRm Axiocam for image acquisition and
densitometric analysis conducted using Axiovision ver-
sion 4.5 software (Carl Zeiss Inc. Thornwood, NY, USA).
Image acquisition was conducted on sections stained
simultaneously and exposed for identical amounts of
time. Quantitation of GFAP staining was performed
using an object area cutoff of 10 μm2 to include cell
bodies and processes. The data were analyzed to deter-
mine the total area covered by positively stained objects
presented as a percentage of the total field of view.
Splenic T cell isolation and analyses
Splenocytes were isolated from mice 10 days after the
booster MOG immunization. After lysis of red blood
cells, splenocytes were plated into 24 well plates at a
density of 2 × 105 cells per well in 400 μl RPMI media
containing 10% fetal calf serum. The cells were restimu-
lated with MOG35-55 peptide (20 μg/ml), or the T cell
receptor (TCR) directly activated with rat monoclonal
anti-CD3 (0.20 μg/ml) and anti-CD28 (0.5 μg/ml) anti-
bodies. Cells were incubated with indicated concentrations
of sevoflurane or equivalent amount of vehicle. After
1 day, aliquots of the media were assayed for levels
of interleukin (IL)-17 and interferon (IFN)γ by ELISA
following the manufacturer’s instructions (eBioscience,
San Diego, CA, USA). Cell proliferation was assessed
indirectly using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay to measure
mitochondrial content; and cell viability after 24 h by
measurement of lactate dehydrogenase (LDH) released
into the media (Promega, Madison, WI, USA).
Data analysis
Comparison of clinical signs over time in one group was
performed via one-way, non-parametric analysis of vari-
ance (ANOVA) (Kruskal-Wallis test) followed by Dunn’s
multiple comparison tests. Comparison of the effect of
treatment versus control on the development of clinical
signs was performed via two-way repeated measures
ANOVA. Two group comparisons were performed by
Mann–Whitney non-parametric unpaired t tests. Effects
of sevoflurane on T cell parameters were compared by
parametric one-way ANOVA followed by Tukey post
hoc comparisons. In all cases significance was taken at
P <0.05.
Results
Sevoflurane attenuates development of clinical signs
of EAE
C57Bl6 mice were immunized with MOG35-55 peptide to
develop a chronic demyelinating disease using a standar-
dized protocol. At day 10 after the booster immunization,
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at which point the mice were just beginning to show clin-
ical signs, they were treated for 2 h with 2.5% sevoflurane
dissolved in 100% oxygen, or with 100% oxygen alone.
Clinical scores were then monitored for the next 4 weeks.
In both groups the incidence of diseases reached 100% at
day 23 (Figure 1A). In the control group, clinical scores
increased over time (Figure 1B) reaching a maximum
value of 2.86 ± 0.46 at day 28; during this time one
mouse died at day 25. In the sevoflurane-treated group,
clinical scores increased similarly to the control group up
until day 25, at which point the scores remained stable
until the end of the study (2.14 ± 0. 15). The difference in
clinical score development in the sevoflurane-treated
mice was statistically different than the control mice
(F[9,1] = 1.98, P = 0.049, two-way repeated measures
ANOVA).
Sevoflurane reduces leukocyte infiltration
At the end of the studies described above, serial sagittal
sections were prepared from brains of the oxygen-
treated and sevoflurane-treated mice for histological and
immunocytochemical analysis. H&E staining to visualize
infiltrating cells (Figure 2) showed that while leukocyte
infiltration could be detected in the cerebellum of both
oxygen-treated and sevoflurane-treated mice, there was
a trend to fewer total number of areas of infiltrates in
the sevoflurane-treated mice. Classification into larger
(>5,000 μm2) and smaller (<5,000 μm2) areas of infil-
trates (Figure 2C) shows that sevoflurane significantly
reduced the number of smaller regions containing infil-
trating cells.
Immunostaining using an antibody to the T cell recep-
tor CD4 (Figure 3) revealed the presence of small CD4+
stained cells throughout the brain and large numbers in
the white matter of the cerebellum of the oxygen-treated
mice. In sevoflurane-treated mice, the number of CD4+
stained cells in this area of the cerebellum was reduced
by 50% (P <0.05).
Sevoflurane reduces glial activation in EAE
During EAE, the production of inflammatory mediators
from infiltrating T cells leads to the activation of paren-
chymal glial cells (astrocytes and microglia) throughout
the brain and spinal cord. A reduction in T cell numbers
could therefore reduce overall glial activation. To test
this, we stained serial sections through the cerebellum
for the astrocyte specific marker GFAP (Figure 4). In
sections from oxygen-treated mice, we observed strong
GFAP staining throughout the cerebellum in both the
white matter and in the Bergmann radial glial cells
(Figure 4A). In the sevoflurane samples (Figure 4B),
GFAP staining in the white matter was much less, and
only minimal staining of Bergmann glial was observed.
Quantitative image analysis confirmed that total GFAP
staining in the cerebellum was significantly reduced by
30% in the sevoflurane-treated mice compared to con-
trols (Figure 4C).
Figure 1 Sevoflurane attenuates development of clinical scores in experimental autoimmune encephalomyelitis (EAE). Female C57Bl/6
mice were immunized with myelin oligodendrocyte glycoprotein (MOG)35–55 peptide to develop EAE as described in the Methods section. At
10 days after the MOG booster, the mice were subjected to 2 h of 2.5% sevoflurane in 100% oxygen (open circles), or 100% oxygen alone
(filled circles). Clinical scores were monitored for the next 4 weeks. (A) Daily incidence of disease over the course of the study for both groups.
(B) Mean ± SEM of average clinical scores of one experiment performed with n = 7 mice per group; similar results were obtained in a second
independent study. F[9,1] = 1.98, P = 0.049, two-way repeated measures analysis of variance (ANOVA).
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Sevoflurane reduces T cell activation in vitro
Reduced leukocyte infiltration into the CNS could be
due, in part, to suppression of T cell activation by sevo-
flurane. To test this possibility, splenic T cells were iso-
lated from MOG-immunized mice and activated in vitro
with MOG peptide or with antibodies to the TCR CD3
and costimulatory receptor CD28 (Figure 5). After 24 h,
the T cells produced significant amounts of proinflamma-
tory cytokines IFNγ (Figure 5A) and IL-17 (Figure 5B)
compared to non-activated cells, and those levels were
greater in the TCR activated cells. In MOG-treated cells,
IFNγ levels were reduced by low does of sevoflurane
(0.20 to 1.0 mM); in CD3/28-treated cells only 1.0 mM
sevoflurane showed a significant reduction. Sevoflurane
at these doses did not significantly reduce IL-17 levels in
the media.
Assessment of mitochondrial content using the MTT
assay showed a significant increase in cell proliferation
due to MOG or to CD3/28 as compared to non-treated
cells (Figure 6A). In MOG-treated cells, proliferation
was reduced by 1.0 mM sevoflurane, whereas in the
CD3/28-treated cells both 0.5 and 1.0 mM sevoflurane
reduced proliferation. Measurements of LDH release
showed that sevoflurane at 0.5 and 1.0 mM significantly
increased cell death in both MOG-treated and CD3/28-
treated cells, but not in vehicle-treated cells.
Discussion
To the best of our knowledge this is the first study to
demonstrate neuroprotective effects due to sevoflurane
inhalation that attenuated the development of clinical
symptoms in experimental autoimmune encephalitis, a
Figure 2 Sevoflurane reduces leukocyte infiltration in experimental autoimmune encephalomyelitis (EAE). Representative sagittal sections
from (A) oxygen-treated and (B) sevoflurane-treated mice were stained with hematoxylin and eosin to detect infiltrating cells. Arrows indicate
large (>5,000 μm2) sites of infiltration; asterisks indicate smaller (<5,000 μm2) sites. The lower images show magnified areas as indicated. (C) The
total number of sites of infiltration was quantified as large or small. Data are mean ± SEM of n = 5 sections per animal, three mice in each of the
two treatment groups; *P <0.05 versus oxygen.
Figure 3 Sevoflurane reduces CD4+ T cells in the cerebellum of experimental autoimmune encephalomyelitis (EAE) mice. Representative
sagittal sections from (A) oxygen-treated and (B) sevoflurane-treated mice were stained with antibody against the CD4 receptor to detect
infiltrating T cells, which are visible as small cells staining throughout the white matter. (C) The total numbers of CD4+ cells per field of view
were quantified. Data are mean ± SEM of n = 5 sections per animal, three mice per group; *P <0.05 versus oxygen. Scale bar is 500 μm.
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Figure 4 Sevoflurane reduces glial activation in cerebellum of experimental autoimmune encephalomyelitis (EAE) mice. Representative
sagittal sections from (A) oxygen-treated and (B) sevoflurane-treated mice were stained with antibody to glial fibrillary acidic protein (GFAP) to
detect activated astrocytes. (C) The total GFAP+ staining per field of view was quantified. Data are mean ± SEM of n = 6 sections per animal,
three mice per group; *P <0.05 versus oxygen. WM, white matter; BG, Bergmann glia.
Figure 5 Sevoflurane modifies T cell cytokine production. Splenic T cells were prepared from C57Bl/6 mice 10 days after the booster myelin
oligodendrocyte glycoprotein (MOG) immunization, and restimulated ex vivo with vehicle, with MOG35-55 peptide (20 μg/ml), or activated
with antibodies to CD3 and CD28 in the presence of the indicated doses of sevoflurane. After 24 h, media levels of (A) interferon (IFN)γ and
(B) interleukin (IL)-17 were determined by specific ELISA. Data are mean ± SEM of n = 4 samples per group; *P <0.05 versus 0 sevoflurane
(one-way analysis of variance (ANOVA), Tukey post hoc test).
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well established model of multiple sclerosis. A single ex-
posure of mice to 2.5% sevoflurane for 2 h arrested the
continuing development of neurological symptoms
related to EAE. This functional neurological protection
was associated with a reduction of inflammatory cells
within the brain and reduced levels of glial cell activa-
tion. In parallel, in vitro studies showed inhibitory
actions of low doses (between 0.20 and 1.0 mM) sevo-
flurane on T cell activation, as indicated by reduced ac-
cumulation of IFNγ in the culture media, reduced cell
proliferation, and increased cell death. These results sug-
gest that low doses of sevoflurane may provide benefit in
EAE by suppression of T cell responses.
To place these studies and methodology in a clinical
context, patients typically receive sevoflurane, which
has a minimum alveolar concentration (MAC) = 1.89,
in the range of 1.5% to 2.5%. Measurements of blood
levels from patients receiving sevoflurane at 1.5% demon-
strated concentrations ranging from 43 to 58 μg/ml or
approximately 0.25 mM [29]. Therefore, in our whole
animal studies and the in vitro studies, concentrations
of sevoflurane of 2.5% and 0.5 mM, respectively, are
within the clinically relevant range during general
anesthesia.
EAE induced by MOG peptide typically results in
onset of clinical symptoms beginning at about day
10 after the booster immunization, with a progressive
worsening that plateaus near day 25. In this study,
the control, oxygen-treated EAE mice reached a maximal
clinical score of 2.86 ± 0.46 on day 28 after the booster
MOG peptide immunization, which reflects modest to
severe neurological injury. In contrast, clinical scores in
the sevoflurane-treated mice plateaued at 2.29 ± 0.15 on
day 23 after immunization, after which there was no
further worsening. These findings suggest that a single
exposure to sevoflurane at an early timepoint during the
development of EAE can attenuate the ultimate magni-
tude of neurological damage, although it is not sufficient
to reverse the initial damage that has already occurred.
Whether longer exposure times, or multiple short
exposures to sevoflurane can induce clinical recovery
is currently under investigation.
Histological evaluation revealed significant reductions
in lymphocytic infiltrates within the cerebellum in the
sevoflurane-treated mice. When characterized as to ei-
ther large (>5,000 μm2) or small (<5,000 μm2) areas of
infiltration, the sevoflurane-treated animals showed a
significant reduction in the number of smaller infiltrates.
The pathophysiological significance of infiltrate size is
not entirely clear but may be due to gradual enlarge-
ment of the earlier forming lesion sites. This suggests
that sevoflurane is unable to prevent the enlargement
Figure 6 Sevoflurane reduces T cell proliferation and induces T cell death. Splenic T cells as described in Figure 5 were assayed after 24 h
for (A) cell proliferation using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; and (B) cell death by measurement of
lactate dehydrogenase (LDH) in the culture media. The data are mean ± SEM of n = 4 samples per group, and are relative to values measured for
vehicle-treated cells with 0 sevoflurane. &P <0.05 versus vehicle, 0 sevoflurane (t test); *P <0.05 versus 0 sevoflurane (one way analysis of variance
(ANOVA), Tukey post hoc test).
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of pre-existing sites of infiltrates; but is able to attenu-
ate development of new, smaller lesions.
Our in vitro studies point to suppressive actions of
sevoflurane on T cells isolated from MOG peptide-
immunized mice. This is consistent with previous stud-
ies which have described induction of apoptosis, or cell
damaging effects of sevoflurane on T cells or lympho-
cytes, at similar or higher doses, or after longer time-
points. For example, in CD3+ T cells, exposure to 8%
sevoflurane, which resulted in a cell culture media con-
centration of 1.17 mM, induced significant cell apoptosis
[10,21]. However exposure to lower doses (2.5%, or
approximately 0.40 mM) did not induce apoptosis. In
normal peripheral lymphocytes [11] after incubation
with sevoflurane at concentrations of 0.5, 1.0, and
1.5 mM it was found that the lowest dose did not
increase markers of apoptosis. Cell damaging effects at
higher doses of sevoflurane have been reported in other
lymphocytes, for example in human B cells, 10 mM
sevoflurane (added as 20 μl of the stock 7.5 M sevo-
flurane into 15.5 ml of saline) induced significant
alterations in heme biosynthesis [7]. Our results show
that a very low dose (0.20 mM) of sevoflurane could
significantly reduce the production of the T helper 1 (Th1)
cytokine IFNγ, but that up to 1.0 mM sevoflurane did
not reduce IL-17. This suggests that sevoflurane dif-
ferentially affects distinct T cell subtypes since these
two cytokines are produced by Th1 and Th17 T cells,
respectively. Further studies using enriched cell popu-
lations will be needed to address this possibility.
The ability of sevoflurane to induce T cell apoptosis
or modify T cell functionality has been reported several
times. As soon as 1 or 2 h after administration of sevo-
flurane (between 1% to 1.5% in oxygen:air mixture) there
was an increase in DNA damage in blood lymphocytes
[9]; in vitro exposure of normal human PBMCs to sevo-
flurane (0.5, 1.0, or 1.5 mm) induced apoptosis as soon
as 6 h after exposure [11]. Similarly, exposure of healthy
adult mice to 3% sevoflurane (1.2 MAC) for 40 minutes
reduced the number of circulating PBMCs and splenic
B cells, but increased CD4+ lymphocytes in the spleen
when measured after 3 days [12], which persisted up
to 9 days after anesthesia exposure [16]. The mechan-
isms by which sevoflurane induces lymphocyte damage
are not clear. However, in vitro studies using human
CD3 T cells showed that sevoflurane suppressed activa-
tion of transcription factor AP-1, which plays a role in
T cell inflammatory activation [18] as well as inducing
apoptosis [10]. These effects also involve protein kinase
cascades including activation of the p38 kinase [21].
Interestingly, many of these effects were not observed
following exposure to desflurane. In addition to indu-
cing apoptosis, sevoflurane, as well as other inhalation
anesthetics, can influence interactions of lymphocytes
with other cell types. For example, sevoflurane increased
binding of platelets to lymphocytes, and increased ex-
pression of P-selectin on the platelets [14]. Sevoflurane
inhibited binding of integrin lymphocyte function asso-
ciated antigen 1 (LFA-1) to its ligand (intercellular adhe-
sion molecule 1 (ICAM-1)) thereby accounting for its
ability to reduce inflammatory activation through the
ICAM-1 signaling pathway [15]. Whether some or all of
these actions of sevoflurane contribute to the beneficial
effects observed in the current study are not known;
however reductions in numbers, inflammatory state, or
migration of T cells (and B cells) would all be expected
to be of benefit to diseases such as MS.
Collectively, the results presented in this study suggest
that sevoflurane provides protection against T cell
mediated neurological inflammation and the subsequent
neurological sequelae resulting from T cell infiltration
into the CNS and associated activation of parenchymal
glial cells. Our immunochemical staining of the cerebel-
lum was limited to CD4+ cells, we cannot rule out that
the beneficial effects of sevoflurane are also due in part
to reduced infiltration of other cell types such as macro-
phages or B cells. Measurements of direct effects of
sevoflurane on neuronal integrity and axonal damage
was beyond the scope of this investigation, but the posi-
tive functional protection raises intriguing possibilities
for the use of inhaled anesthetic agents in the treatment
of neuroinflammatory conditions. These conditions need
not be confined solely to primary CNS diseases but
viewed in a more global context of inflammation, such
as sepsis, that results in wide spread inflammation in-
cluding in the brain [30-32].
There has been significant interest in the effects of
inhalational anesthetics on neuronal function (for ex-
ample, anesthesia conditioning and protection) but also
concern due to increased neuronal apoptosis following
exposure to inhaled anesthetics. Widespread concern
regarding the effects of inhalational anesthetics on the
developing brain was the impetus for the SMARTTots
(Strategies for Mitigating Anesthesia-Related neuroTox-
icity in Tots) program (formerly called SAFEKIDS), and
US Food and Drug Administration (FDA)-driven panels
to investigate potential long term sequelae of anesthesia
in pediatric patients [33]. The concern regarding long
term outcomes following exposure to inhalational agents
arose on the heels of significant excitement related to
widespread demonstration of protective effects of
anesthesia preconditioning and even anesthesia post-
conditioning in a variety of models including stroke,
myocardial infarction and ischemia reperfusion injury.
Unraveling the protective effects from injurious effects
has proved to be challenging. In a recent review [34], it
is apparent that the effects of inhalational anesthetics
on the brain are complex and multifactorial and are
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dependent upon subject age, comorbidities, duration of
exposure, concentration and specific anesthetic agent.
Collectively, it appears that higher concentrations and
longer durations of exposure may be associated with
increased neuronal cell death while lower concentrations
may confer neuroprotection.
Conclusions
The current findings demonstrate that a single exposure
to the inhaled anesthetic sevoflurane attenuates the pro-
gression of EAE, associated with reductions in glial cell
activation and T cell infiltration. This raises the possibil-
ity that patients with autoimmune-based neurological
diseases such as MS could also benefit from a similar
treatment.
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MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; MTT: 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBMC: peripheral
blood mononuclear cells; PBS: phosphate-buffered saline; PT: pertussis toxin;
RRX: rhodamine red-X; TCR: T cell receptor; Th1: T helper 1; Th17: T helper 17.
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